ClinicalTrials.gg
CompletedNCT05407246Updated Jan 11, 2024

Phase II Study of Hemay005 in Patients With Active Ankylosing Spondylitis

A Phase 2 interventional study of Hemay005 in Active Ankylosing Spondylitis, sponsored by Tianjin Hemay Pharmaceutical Co., Ltd. Completed at 11 sites in China. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2024-01-11.

Sponsored by Tianjin Hemay Pharmaceutical Co., Ltd · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
90
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 76 studies in Spondylitis, Ankylosing with a site in China — 19 open to participants now, 22 under way, 4 of them phase 3. Spondylitis, Ankylosing · China.

Enrollment
44th of 62
90 · median 150
Started
2022
with 2 others
Phase 2
11 of 76
none open now
Registered
47th of 76
by date

Among the 76 studies in Spondylitis, Ankylosing with a site in China, this one is the 44th largest by enrollment of the 62 interventional ones that give a count, is one of 3 that started in 2022, is one of 11 in phase 2, and was the 47th registered.

Spondylitis, Ankylosing

533 studies on the registry are indexed under Spondylitis, Ankylosing; 99 are open to participants now.

Browse Spondylitis, Ankylosing studies →

Open to participants now

19 of the 76 studies in Spondylitis, Ankylosing with a site in China are open now. Recruiting first, the newest first:

14 more — sign in →

All 19 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 63 Spondylitis, Ankylosing studies recruiting now, 25 (40%) set no upper age limit and 32 (51%) stop at 75 or younger; 10 take children under 18; 15 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 76 studies in Spondylitis, Ankylosing with a site in China, or all of them as a file.
02

Study summary

This study is a multicenter, randomized, double-blind, placebo-controlled phase II clinical study. The study was divided into three stages, including screening period(4-week), treatment period(16-week) and observation period. All subjects need to enter a 28 day (4-week) observation period after stopping hemay005 treatment.

Main purpose:

The efficacy of hemay005 tablet in the treatment of active ankylosing spondylitis (as) was evaluated by placebo parallel control.

Secondary purpose:

  • To evaluate the safety of oral hemay005 tablets in patients with active as.
  • To evaluate the population pharmacokinetics of hemay005 tablets in patients with active as.
Read the detailed description

This study is a multicenter, randomized, double-blind, placebo-controlled phase II clinical study. The study was divided into three stages, including screening period, treatment period and observation period. All subjects need to enter a 28 day (4-week) observation period after stopping hemay005 treatment.

Screening period: all subjects shall have a screening period of no more than 28 days (4 weeks) before the baseline visit (day 1 of randomization).

Treatment period: after screening and meeting the inclusion requirements of the study, as subjects were randomly divided into hemay005 60 mg twice daily (bid) dose group (group A), 75 mg bid dose group (group B) and placebo control group (Group C) according to the ratio of 1:1:1. A total of 90 subjects were included in the three groups. They were titrated in the first 6 days. From the 7th day, the subjects received fixed dose administration twice a day for 112 consecutive days (16 weeks). Considering the difference in the proportion of men and women with as, and the slow onset and mild condition of women, randomization will minimize the imbalance between treatment groups according to gender stratification.

Observation period: Subjects in the study (including those who withdrew from the treatment early for any reason) shall be observed for 4 weeks after the end of the last administration.

Main purpose:

The efficacy of hemay005 tablet in the treatment of active ankylosing spondylitis (as) was evaluated by placebo parallel control.

Secondary purpose:

  • To evaluate the safety of oral hemay005 tablets in patients with active as.
  • To evaluate the population pharmacokinetics of hemay005 tablets in patients with active as.
03

Conditions studied

  • Active Ankylosing Spondylitis
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Understand and voluntarily sign the form of this study.
  • Aged between 18 and 65 years old (both ends included, subject to the date of signing the informed consent form), male or female.
  • 50 kg ≤ male weight \<100 kg, 45 kg ≤ female weight \<100 kg.
  • The results of human leucocyte antigen (HLA) -b27 were positive.
  • Be able to comply with the follow-up schedule and other protocol requirements
  • As (revised New York standard 1984) was diagnosed as follows:

    1. Low back pain lasted for at least 3 months. The pain improved with activity, but the rest did not reduce;
    2. The movement of lumbar vertebra in the direction of anteroposterior and lateral flexion was limited;
    3. The extension range of thorax was smaller than the normal value of the same age and sex;
    4. Bilateral sacroiliac arthritis grade II \~ IV, or unilateral sacroiliac arthritis grade III \~ IV.

If the patient has 4) and adds any one of 1) \~3) respectively, it can be diagnosed as as;

  • The subjects shall at least meet the requirements of 1) and 2) below:

    1. Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) ≥ 4, and chronic low back pain ≥ 4 (patient back pain intensity assessment question 1) (NRS score);
    2. At least one nonsteroidal anti-inflammatory drugs (NSAIDs) was used before randomization, but the symptoms were not relieved or the drugs were intolerable or there were drug , that is, at least 4 weeks of stable use of 1 NSAID at the recommended dose or ≥ 2 NSAIDs, each NSAID was used stably for ≥ 2 weeks) or intolerable before randomization;
    3. In case of any of the following three criteria, the subject shall also meet the corresponding provisions:

    <!-- -->

    1. Patients who are receiving NSAIDs, oral (prednisone with daily oral glucocorticoid dose ≤ 10 mg or other equivalent dose) and / or cyclooxygenase-2 (COX-2) inhibitors, the dosage is stable at least 14 days before randomization and throughout the study period;
    2. For patients with combined use of sulfasalazine: subjects who began to take sulfasalazine [≤ 3 g/ day] at least 12 weeks before randomization and whose dose and route of administration have been stable for at least 4 weeks before randomization can continue to take sulfasalazine at a sustained dose during the study period;
    3. For previous use of tumor necrosis factor (TNF)- α Patients with inhibitors: TNF α Subjects with inhibitors did not respond adequately to the approved dose for at least 12 weeks, or did not tolerate the treatment;
  • The following laboratory standards must be met:

(HB) ≥ 9 g/dl Hematocrit ≥ 27% White blood cell (WBC) count ≥ 3000/ μ L(≥3.0 × 109/l) and \<20000/ μ L(\<20 × 109/L) Neutrophil (neu) ≥ 1500/ μ L(≥1.5 × 109/L) (PLT) ≥ 100000/ μ L(≥100 × 109/L) Serum creatinine (CR) ≤ 1.5 mg/dl (≤ 132.6 μ mol/L) Total (TBIL) ≤ 2.0 mg/dl , AST (serum glutamic oxaloacetic transaminase, SGOT) and alanine aminotransferase, ALT (serum glutamic pyruvic transaminase, SGPT)] ≤ 1.5 times the (ULN);

  • During the whole study period since the signing of the informed consent and within 3 months after the last administration of the study drug, Female subjects with fertility and male subjects without vasectomy are willing to take effective measures [effective contraceptive measures include vasectomy, abstinence, intrauterine device (IUD), hormones (oral, patch, ring, injection, implantation) and barrier method (diaphragm, cervical cap, sponge, condom)]; The serum pregnancy test [human chorionic gonadotropin (hCG)] of fertile female subjects within the first 7 days of randomization must be negative; Male subjects could not donate sperm within 3 months after the first administration of the study drug to the last Administration [Note: fertility is defined as: non menopausal women who have experienced menarche, have not undergone sterilization (hysterectomy / bilateral oophorectomy / bilateral tubal ligation), and have undergone sterilization but have not completed 6 months (menopause refers to continuous natural menopause ≥ 12 months)].

Exclusion criteria

Exclusion Criteria:

  • Have the following diseases or disease history:

    1. Complete rigidity of spine or complete fusion of sacroiliac joint;
    2. Patients with a history of other rheumatic diseases (such as systemic lupus erythematosus, rheumatoid arthritis, etc.);
    3. Patients with a history of tuberculosis or active tuberculosis (there are signs or symptoms of active tuberculosis judged by the researcher at the time of screening):

      If the patient has a previous history of tuberculosis and has been cured for at least 3 years before randomization according to the researcher's assessment, screening is allowed; Subjects with negative T-SPOT during screening can be included in this study. Subjects with positive T-SPOT in the screening period need to undergo tuberculosis related clinical examination (tuberculosis related clinical examination conducted within 12 weeks before randomization can be directly used for evaluation). If tuberculosis related clinical examination is confirmed as active tuberculosis, subjects cannot be selected for this study; If tuberculosis related clinical examination confirms inactive tuberculosis, the subject can be included in this study. If the research center is unable to carry out T-SPOT test, it can also accept tuberculosis screening with QuantiFERON TB gold test kit. The processing of QuantiFERON TB gold screening results is the same as that of T-SPOT;

    4. Patients with malignant tumor or any history of malignant tumor within 5 years before screening (except skin squamous cell carcinoma in situ, basal cell carcinoma or cervical carcinoma in situ after treatment and no recurrence evidence in the past 12 weeks);
    5. Evidence of active infection within 1 month before screening, including acute and chronic infection and local infection, such as sepsis, abscess, cellulitis and opportunistic fungal (such as Candida) infection (which can be judged by the research doctor in combination with the specific situation of the patient);
    6. Patients with severe basic diseases, such as heart, lung, kidney, liver, nerve, endocrine, gastrointestinal, metabolic or hematological diseases, moderate to severe congestive heart failure ( grade III or IV);
    7. Have a history of alcohol or drug abuse or dependence, or a history of mental illness;
    8. Situations that may affect the absorption of oral drugs, such as subtotal gastrectomy, diabetes gastroenteropathy, or some types of weight loss surgery such as gastric bypass surgery, do not include operations that simply partition the stomach into a separate chamber, such as gastric banding surgery;
  • Pregnant or lactating women;
  • Those who are allergic or allergic to the study drug or its preparation components;
  • Those who have undergone major surgery (including spinal surgery or joint surgery) within the first 6 months or plan to undergo major surgery during the trial;
  • Those who have participated in clinical trials of any drugs or medical devices within the first three months of screening;
  • Those who plan to receive attenuated or during the test;
  • Taking or having the following medication history:

    1. Patients who used disease modifying anti rheumatic drugs (DMARDs) methotrexate, penicillamine, sulfasalazine, azathioprine and hydroxychloroquine within the first 4 weeks of randomization, except those who used sulfasalazine at a stable dose, and other unlisted abiotic agents were eluted according to 5 drug half lives (or 4 weeks, whichever is longer);
    2. Intravenous or articular endothelium were used within the first 4 weeks of randomization;
    3. Etanercept, adalimumab, efuzumab, infliximab and afacept were used within 8 weeks before randomization, and other unlisted biological agents were eluted according to 5 drug half lives (or 8 weeks, whichever is longer);
    4. Those who used apster before randomization;
    5. Those who used strong cytochrome P450 enzyme inducers within 4 weeks before randomization (e.g., rifampicin, phenobarbital, carbamazepine, phenytoin sodium);
    6. Those who used Tripterygium Wilfordii and other proprietary Chinese medicine or traditional Chinese medicine decoction within 2 weeks before randomization;
  • There are any clinically significant abnormalities in 12 lead at the time of screening, and the researcher assessed that participating in this study may increase the risk of subjects or interfere with data interpretation;
  • Patients with clinically significant abnormalities in chest X-ray (CXR) or computed tomography (CT) during screening, and the researchers may put the subjects at safety risk;
  • subjects with positive B surface antigen (HBsAg), virus antibody (HCVAb), antibody (hivab) or Treponema pallidum antibody;
  • Have committed suicide (including active attempt, interrupted attempt or attempted attempt) or have suicidal thoughts in the past 6 months;
  • The researcher believes that there are any other circumstances that are not suitable for participating in the trial.
Terms in these criteria, in plain language(17)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
90 participants (actual)

Study arms

  • Active comparator
    Hemay005 75mg BID group

    75mg BID of Hemay005; daily oral administrtion for 16 weeks

    Drug: Hemay005

  • Active comparator
    Hemay005 60mg BID group

    60mg BID of Hemay005; daily oral administrtion for 16 weeks

    Drug: Hemay005

  • Placebo comparator
    placebo group

    Placebo of Hemay005; daily oral administrtion for 16 weeks

    Drug: Hemay005

Interventions

  • Hemay005 60 mg treatment group (group A): hemay005 tablets 60 mg bid were used during the treatment period; Hemay005 75 mg treatment group (group B): hemay005 75 mg bid was used during the treatment period; Placebo group (Group C): placebo (hemay005 tablet simulant) bid was used during the treatment period;

    Also known as: placebo

06

What researchers measure

Primary outcomes

  1. ASAS20

    The proportion of subjects who achieved ASAS 20 remission at the week 16,higher proportion means better effecacy of Hemay005.

    Time frame: week 16

Secondary outcomes

  1. BASFI

    Changes of Ankylosing Spondylitis Functional Index (BASFI), the more scores change means a better outcome.

    Time frame: week 2, 4, 8, 12 and 16

  2. BASDAI

    Changes of Ankylosing Spondylitis Functional Index (BASDAI),the more scores change means a better outcome.

    Time frame: week 2, 4, 8, 12 and 16

  3. ASAS20

    The proportion of subjects who achieved ASAS 20 remission,higher proportion means better effecacy of Hemay005.

    Time frame: week 2, 4, 8, 12

  4. ASAS40

    The proportion of subjects who achieved ASAS 40 remission,higher proportion means better effecacy of Hemay005.

    Time frame: week 2, 4, 8, 12 and 16

  5. ASQoL

    Changes in total scores of ankylosing spondylitis quality of life (asqol),the more scores change means a better outcome.

    Time frame: week 16

  6. BASMI

    Changes in the Bath Ankylosing Spondylitis measurement index (BASMI),the more scores change mean a better outcome.

    Time frame: week 2, 4, 8, 12 and 16

  7. hs-CPR

    Changes of hypersensitive C-reactive protein (hs CRP) ;

    Time frame: week 2, 4, 8, 12 and 16

  8. MASES

    Changes of Maastricht ankylosing spondylitis adhesion score (MASES),the more scores change mean a better outcome.

    Time frame: week 2, 4, 8, 12 and 16

  9. Extraarticular manifestations

    Extraarticular manifestations,,(Such as uveitis, inflammatory bowel disease and psoriasis), and record the history (existence) of these manifestations and the new occurrence or deterioration of these manifestations;

    Time frame: week 2, 4, 8, 12 and 16

  10. ESR

    Changes of erythrocyte sedimentation rate (ESR) in acute phase;

    Time frame: week 2, 4, 8, 12 and 16

07

Study locations

11 sites
  • The First Affiliated Hospital of Bengbu Medical University
    Hefei, Anhui 233000, China
  • Peking Union Medical College Hospital, Chinese Academy of Medical Sciences
    Beijing, Beijing 100000, China
  • Guangdong Provincial People's Hospital
    Guangzhou, Guangdong 510080, China
  • The Third Affiliated Hospital of Sun Yat sen University
    Guangzhou, Guangdong 510275, China
  • Hebei CNPC Central Hospital
    Langfang, Hebei 05001, China
  • Puyang Oilfield General Hospital
    Puyang, Henan 457001, China
  • Tongji Hospital Affiliated to Tongji Medical College of Huazhong University of science and technology
    Wuhan, Hubei 430000, China
  • Chenzhou first people's Hospital
    Chenzhou, Hunan 423099, China
  • Pingxiang people's Hospital
    Pingxiang, Jiangxi 337099, China
  • Jilin Provincial People's Hospital
    Changchun, Jilin 130021, China
  • The First Affiliated Hospital of Medical College of Xi'an Jiaotong University
    Xi'an, Shanxi 71000, China
08

References and documents

Individual participant data

Plan to share: No — It is yet decided not to share the individual participant data (IPD) to other researchers.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Aug 2022 to primary completion in Aug 2023, 12 months.

Of 22 phase 2 interventional studies under Spondylitis, Ankylosing, half reached primary completion within 15 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 31. This study's 12 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
May 30, 2022
First posted
Jun 7, 2022
StartActual
Aug 5, 2022
Primary completionActual
Aug 18, 2023
CompletionActual
Aug 18, 2023
Last update
Jan 11, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 11, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05407246
Lead sponsor
Tianjin Hemay Pharmaceutical Co., Ltd
Responsible party
Sponsor
First posted
Jun 7, 2022
Start date
Aug 5, 2022
Primary completion
Aug 18, 2023
Completion
Aug 18, 2023
Last update
Jan 11, 2024

Study contacts

Xiaofeng Zeng, M.D
principal investigator · Peking Union Medical College

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Hemay005

Start the discussion